Advertisement

Fluconazole in Mucosal Candidosis

Preliminary Results in Oropharyngeal Candidosis
  • E. Tümbay
  • B. Üçer
  • G. Karakartal
  • A. Bilgiç
  • R. İnci
  • M. A. Özinel
  • A. Havuk
  • M. Tüker
  • O. Demir
Part of the Federation of European Microbiological Societies Symposium Series book series (FEMS, volume 50)

Abstract

Fluconazole, (Flu), a novel triazole derivative administered both orally and intravenously, has been used particulary in the treatment of superficial and systemic Candida infections and cryptococcosis. The drug has good pharmacokinetic properties: It is promptly absorbed shortly after oral intake, is diffused extensively into cerebrospinal fluid and other body fluids, shows low binding to plasma proteins, has a plasma half-life of 25–29 hours, and is excreted by the kidneys 75–90% in bioactive form. Its toxicity is low and side effects are encountered in less than 1% of the patients1.

Keywords

Antifungal Agent Clinical Cure Oropharyngeal Candidiasis Esophageal Candidiasis Oropharyngeal Swab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    E.Tümbay, Sistemik etkili yeni bir antifungal kemoterapötik: (Fluconazole, a novel antifungal agent with systemic effect), znfeks. Derck., 3 (1), Ek Baski Seri No. 1 (Suppl. 1), 27 pp. (1989).Google Scholar
  2. 2.
    J.P.Bodey, G.Samonis, K.Rolston, Prophylaxis of oropharyngeal candidiasis with fluconazole, in: “Abstracts of the Fifth International Symposium on Infections in the Immunocompromised Host, June 1988, Noordwijkerhout, The Netherlands” (1988).Google Scholar
  3. 3.
    K.W.Brammer, P.R.Farrow, J.M.Feczko, Fluconazole, a new systemically effective antifungal agent for use in hospitalized patients, in: “Abstracts of the Fifth International Conference of the Hospital Infection Society, August 1987, London” (1987).Google Scholar
  4. 4.
    K.W.Brammer, J.M.Feczko, R.R.G.Leeming, Fluconazole in the treatment of systemic candidosis and cryptococcal infections, in: “Abstracts of the Tenth Congress of the International Society for Human and Animal Mycology, June 1988, Barcelona” (1988).Google Scholar
  5. 5.
    N.Clumeck, S.De Wits, D.Weerts, P.Hermans, F.De Cock, Double-blind randomized study of oral fluconazole (F) versus ketoconazole (K) in 40 episodes of oropharyngeal candidiasis (DC) in ARC/AIDSGoogle Scholar
  6. 6.
    Patients P,in: “Abstracts of Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies (2nd BICON)”, Abstract No. 83 7h1. Antineoplas. Chemother.,Suppl. 1 (1989).Google Scholar
  7. 7.
    P.Dellamonica, E Bernard, Y.Lefichoux, M.Carles, S.Politano, Fluconazole treatment of amphotericin B resistant mucosal candidiasis infection in AIDS patients, in: “Abstract of the Fifth International Symposium on Infections in the Immunocompromised Host, June 1988, Noordwijkerhout, The Netherlands” (1988).Google Scholar
  8. 8.
    B.Dupont and E.Drouhet, Fluconazole in the management of oro-pharyngeal candidiasis in predominantly HIV antibody-positive group of patients, in: “Recent Trends in the Discovery, Development and Management of Antifungal Agents”, R.A. Fromtling, ed., pp. 163–168, Prous Science Publishers, Barcelona (1987).Google Scholar
  9. 9.
    A.Gil, P.Lavillame, M.E.Valencia, V.Pintado, J.M.L.Dupla, J.Lahuerta, Fluconazole treatment of esophageal candidiasis in AIDS patients, in: “Abstracts of Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies (2nd BICON), 5–8 March 1989, Montreux, Switzerland”, Abstract No. 79, Zbl. Antimikrob. Antineoplas. Chemother. Suppl. 1 (1989).Google Scholar
  10. 10.
    R.J.Hay, Overview of studies of fluconazole in oropharyngeal candidiasis, in:“Fluconazole Symposium Abstracts, 8–9 October 1988, Dorado, Puerto Rico”, p. 20 (1988).Google Scholar
  11. 11.
    F.Meunier, Therapy of candidiasis in the immunocompromised host, in: “Fluconazole Symposium Abstracts, 8–9 October 1988, Dorado, Puerto Rico”, p. 26 (1988).Google Scholar
  12. 12.
    F.Meunier, M.Aoun, M.Gerhard, N.Delhaye, Therapy of oro-pharyngeal candidiasis in the immunocompromised host, in: “Abstracts of Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies (2nd BICON), 5–8 March 1989, Montreux, Switzerland”, Abstract No$170, Zbl. Antimikrob. Antineopl_as. Chemother., Suppl. 1 (1989).Google Scholar
  13. 13.
    F.Meunier, J.Gerain, R.Snoek, F.Libotte, C.Lambert, A.M.Cueppens, Fluconazole therapy of oropharyngeal candidiosis in cancer patients, in: “Recent Trends in the Discovery, Development and Management of Antifungal Agents”, R.A. Fromtling, ed., pp. 169–174, Prous Science Publishers, Barcelona (1987).Google Scholar
  14. 14.
    P.A.Robinson, A.K.Knirsch, J.A.Joseph, Fluconazole treatment of serious fungal infections in patients who have failed conventional antifungal therapy, iß: “Fluconazole Symposium Abstracts, 8–9 October 1988, Dorado, Puerto Rico”, p. 25 (1988).Google Scholar
  15. 15.
    D.A.Stevens, E.Brummer, J.G.McEwen, A.Perlman, Efficacy of fluconazole, a new oral triazole, in blastomycosis and in comparison with ketoconazole, in: “Fluconazole Symposium Abstracts, 8–9 October 1988, Dorado, Puerto Rico, p. 16 (1988).Google Scholar
  16. 15.
    P.F.Wragg, R.A.Howell, P.Hardy, P.J.Farrelly, M.V.Martin, An open non-comparative trial of fluconazole, a new systemically administered antifungal, J.Dent.Res.., 65: 515 (1986).Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • E. Tümbay
    • 1
  • B. Üçer
    • 2
  • G. Karakartal
    • 3
  • A. Bilgiç
    • 1
  • R. İnci
    • 4
  • M. A. Özinel
    • 1
  • A. Havuk
    • 5
  • M. Tüker
    • 6
  • O. Demir
    • 1
  1. 1.Department of Microbiology, Faculty of MedicineEge UniversityBornoya, IzmirTurkey
  2. 2.Anesthesiology/Intensive Care SectionSSK Buca HospitalBuca, IzmirTurkey
  3. 3.Department of Clinical Bacteriology and Infectious Diseases, Faculty of MedicineEge UniversityBornoya, IzmirTurkey
  4. 4.Specialist of Bacteriology and Infectious DiseasesBatmanTurkey
  5. 5.Microbiology/Infectious Disease SectionSSK Buca HospitalBuca, IzmirTurkey
  6. 6.Microbiology/Infectious Disease SectionIzmir State HospitalYeşilyurt, IzmirTurkey

Personalised recommendations